Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBT Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBT Margin for 3 consecutive years, with 2204.0% as the latest value for Q2 2025.

  • On a quarterly basis, EBT Margin fell 186021700.0% to 2204.0% in Q2 2025 year-over-year; TTM through Sep 2025 was 12031.34%, a 3772654.0% increase, with the full-year FY2024 number at 843787.0%, up 85710500.0% from a year prior.
  • EBT Margin was 2204.0% for Q2 2025 at Inhibrx Biosciences, down from 1610.67% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1858013.0% in Q2 2024 to a low of 129750.0% in Q2 2023.
  • A 3-year average of 209472.44% and a median of 784.25% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 198776300bps in 2024, then crashed -186021700bps in 2025.
  • Inhibrx Biosciences' EBT Margin stood at 5628.76% in 2023, then tumbled by -750bps to 47865.0% in 2024, then soared by 95bps to 2204.0% in 2025.
  • Per Business Quant, the three most recent readings for INBX's EBT Margin are 2204.0% (Q2 2025), 1610.67% (Q1 2025), and 47865.0% (Q4 2024).